Predict your next investment

Corporation
HEALTHCARE | Drug Delivery
sirion-biotech.com

See what CB Insights has to offer

Founded Year

2005

Stage

Acquired | Acquired

About Sirion Biotech

SIRION Biotech is a viral vector technology company for gene and cell therapy, including vaccine development. The company offers comprehensive viral vector technology platforms based on lentiviruses, adenoviruses, and adeno-associated viruses (AAV) custom engineering, and manufacturing to expedites gene therapy research, cell therapy research, and advance drug development. It is based in Martinsried, Germany.On June 22, 2021, Sirion Biotech was acquired by PerkinElmer. The terms of the transaction were not disclosed.

Sirion Biotech Headquarter Location

Am Klopferspitz 19

Martinsried, 82152,

Germany

+49 89 700 961 99 9

Latest Sirion Biotech News

Webinar: Developing Lentiviral Vectors for ex vivo and in vivo Gene Therapy

Oct 26, 2021

) SIRION Biotech, the leading German viral vector company, will present a Webinar on November 17 at 2 PM GMT discussing optimizing lentivirus vector design for improved quality and safety Optimizing the safety of lentiviral vectors has been one of the main focal points of lentiviral vector development. Likewise, the design of the lentiviral backbone and the therapeutic payload cassette can influence the manufacturability of the particles, for example their quality and potency features. Optimizing those features will further improve the safety and efficacy profile of future ex vivo and in vivo gene therapies. To date the safety of over 25 lentivirus backbones has been tested in more than 200 clinical trials. SIRION Biotech will discuss the main features of those backbones and the main strategies to further optimize their safety. We will also give insights into datasets from our Viral Vector Know-How Hub to illustrate how payload design strategies can affect the manufacturability of the lentiviral particles and their usage to develop ex vivo and in vivo gene therapies. Our Viral Vector Know-How Hub includes data derived from over 6,000 lentiviral vectors. We will also present a complementary strategy to optimize cell transduction by using LentiBOOST®, a chemical transduction enhancer currently used in more than 20 Phase I/II and III clinical trials, as part of developing a cGMP-compliant process to manufacture CD19-CAR T cells. For more information about the Webinar, and to sign up to attend, please visit https://www.sirion-biotech.com/... Website Promotion SIRION BIOTECH GmbH SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world's most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite gene therapy research and advance drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST® has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector. Das könnte Sie auch interessieren 14.10.2021

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sirion Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sirion Biotech is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Sirion Biotech Patents

Sirion Biotech has filed 7 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/30/2017

10/26/2021

Molecular biology, Transcription factors, Biotechnology, Genetics, Virology

Grant

Application Date

1/30/2017

Grant Date

10/26/2021

Title

Related Topics

Molecular biology, Transcription factors, Biotechnology, Genetics, Virology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.